Anti-Mouse MHC Class II (I-A) [Clone Y-3P] – Purified in vivo GOLD™ Functional Grade
Anti-Mouse MHC Class II (I-A) [Clone Y-3P] – Purified in vivo GOLD™ Functional Grade
Product No.: H470
Clone Y-3P Target MHC class II (I-A) Formats AvailableView All Product Type Hybridoma Monoclonal Antibody Isotype Mouse IgG2a k Applications B , FC |
Antibody DetailsProduct DetailsReactive Species Mouse Host Species Mouse Recommended Dilution Buffer Immunogen BALB/c x C57BL/6 F1 mouse spleen cells Product Concentration ≥ 5.0 mg/ml Endotoxin Level < 1.0 EU/mg as determined by the LAL method Purity ≥95% monomer by analytical SEC ⋅ >95% by SDS Page Formulation This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration. State of Matter Liquid Product Preparation Functional grade preclinical antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates. Storage and Handling Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles. Regulatory Status Research Use Only Country of Origin USA Shipping 2 – 8° C Wet Ice Additional Applications Reported In Literature ? B, FC Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change. DescriptionDescriptionSpecificity Y-3P activity is directed against mouse MHC class II (I-A) glycoprotein antigens,
including the haplotypes I-Ab, I-Af, I-Ap, I-Aq, I-Ar, I-As, I-Au, I-Av, and weakly I-Ak. Y-3P
also reacts with the equivalent complexes in rats. Background H-2, the murine major histocompatibility complex (MHC), is composed of a diverse group of
antigens divided into class I and II proteins that function in immune response1. Class II
molecules, also known as Ia antigens, regulate recognition of foreign antigens on the surfaces of
antigen presenting cells and play a major role in the mixed lymphocyte response2. Mice have
two class II isotypes, I-A and I-E, each of which is a glycoprotein composed of an ⍺ and β
subunit. The N-terminal α1 and β1 domains of the MHC class II isotype form the antigen-
binding groove, which binds 13-25 aa peptides derived from exogenous antigens3. On APCs, MHC class II molecules play a critical role in the adaptive immune response by presenting phagocytosed antigens to helper CD4 T cells. The T cell receptor (TCR)/CD3 complex of CD4 T cells interacts with peptide-MHC class II, which induces CD4 T cell activation leading to the coordination and regulation of other effector cells. CD4 molecules also bind to MHC class II, which helps augment TCR signaling4. Additionally, MHC class II expressed on activated T cells are capable of antigen presentation5 and can transduce signals into T cells, enhancing T cell proliferation and activity6. Y-3P was generated by repeatedly immunizing primed mice with activated T cells over the course of a year7. Y-3P reacts with I-A subregion-controlled A ⍺: A β complexes of all mouse strains except the responder strain H-2d. Y-3P is commonly used for in vivo blockade of TCR stimulation8,9 and MHC class II blocking10,11,12,13,14,15. Antigen Distribution MHC class II molecules are constitutively expressed on professional
antigen-presenting cells (APCs), including macrophages, monocytes, dendritic cells (DCs), and
B cells, and are induced on T cells upon activation. Ligand/Receptor CD3/TCR, CD4 NCBI Gene Bank ID UniProt.org Research Area Immunology . Innate Immunity Leinco Antibody AdvisorPowered by AI: AI is experimental and still learning how to provide the best assistance. It may occasionally generate incorrect or incomplete responses. Please do not rely solely on its recommendations when making purchasing decisions or designing experiments. Clone Y-3P is widely used in mice for in vivo blockade of MHC class II (I-A) molecules, primarily to inhibit I-A-restricted T cell responses or manipulate antigen presentation, making it a key tool in immunological blockading and functional studies. Common in vivo applications include:
Summary table:
Y-3P is reported to react with various I-A haplotypes (I-A^b^, I-A^f^, I-A^p^, etc.), allowing use across multiple mouse strains. Its specificity is to the I-A subtype, not I-E. Typical in vivo applications focus on immune blockade experiments where antigen-specific MHC II:T cell interactions need to be interrupted. These uses are broadly supported by product documentation, research antibody suppliers, and peer-reviewed studies using Y-3P for in vivo immunological modulation. Commonly, Y-3P (an anti-mouse MHC class II antibody) is used alongside antibodies and proteins targeting T cell activation and differentiation, especially in immunological studies focused on antigen presentation and T cell responses. Frequently co-used antibodies and proteins include:
In experimental setups, researchers often combine Y-3P with these antibodies in:
Other relevant antibodies can include isotype controls (e.g., Mouse IgG2a), specific peptide:MHC II–recognizing antibodies such as Y-Ae (for Eα:IA^b complexes), or anti-MHC II antibodies that recognize different haplotypes for comparative or blocking studies. These combinations are essential for characterizing cell interactions within the immune response and for functional studies of antigen presentation, tolerance, and transplantation immunology. Clone Y-3P is a widely used monoclonal antibody that targets mouse MHC class II (I-A) molecules, and its citations in scientific literature reveal several key applications and findings:
In summary, Y-3P is a foundational tool antibody in mouse immunology, providing specific blockade, detection, and mechanistic interrogation of MHC class II (I-A)-mediated processes throughout the literature. Its versatility and specificity are reflected in many landmark immunological publications. Dosing regimens for the Y-3P clone, which targets mouse MHC class II (I-A), can vary significantly across different mouse models. The dosing strategy often depends on several factors, including:
A typical dosing range for functionally similar MHC class II blocking antibodies, such as Y-3P, is generally between 100–250 μg per mouse. However, specific dosing regimens in the literature may vary based on the experimental design and desired outcomes. Investigators often need to determine their own optimal working dilution and dosing schedule based on the specific requirements of their study. For precise dosing, it is crucial to consult the specific literature related to the mouse model being used, as dosing can significantly impact the efficacy and relevance of experimental results. References & Citations1. Yoshida R. Adv Immunol. 124:207-247. 2014. 2. Spencer JS, Kubo RT. J Exp Med. 169(3):625-640. 1989. 3. Wieczorek M, Abualrous ET, Sticht J, et al. Front Immunol. 8:292. 2017. 4. Artyomov MN, Lis M, Devadas S, et al. Proc Natl Acad Sci USA. 107(39):16916-16921. 2010. 5. Barnaba V, Watts C, de Boer M, et al. Eur J Immunol. 24(1):71-75. 1994. 6. Di Rosa F, D'Oro U, Ruggiero G, et al. Hum Immunol. 38(4):251-260. 1993. 7. Janeway CA Jr, Conrad PJ, Lerner EA, et al. J Immunol. 132(2):662-667. 1984. 8. Feng Y, van der Veeken J, Shugay M, et al. Nature. 528(7580):132-136. 2015. 9. Campisi L, Barbet G, Ding Y, et al. Nat Immunol. 17(9):1084-1092. 2016. 10. Stefanová I, Dorfman JR, Germain RN. Nature. 420(6914):429-434. 2002. 11. Andersson J, Stefanova I, Stephens GL, et al. Int Immunol. 19(4):557-566. 2007. 12. Younes SA, Punkosdy G, Caucheteux S, et al. PLoS Biol. 9(10):e1001171. 2011. 13. Guo L, Huang Y, Chen X, et al. Nat Immunol. 16(10):1051-1059. 2015. 14. Kawabe T, Yi J, Kawajiri A, et al. Nat Commun. 11(1):3366. 2020. 15. Kruse B, Buzzai AC, Shridhar N, et al. Nature. 618(7967):1033-1040. 2023. 16. Wei J, Loke P, Zang X, et al. J Exp Med. 208(8):1683-1694. 2011. 17. Alspach E, Lussier DM, Miceli AP, et al. Nature. 574(7780):696-701. 2019. 18. Hos BJ, Tondini E, Camps MGM, et al. Cell Rep. 41(2):111485. 2022. Technical ProtocolsCertificate of Analysis |
Formats Available
